Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis

Thirusha Lane; Marianna Fontana; Ana Martinez–Naharro; Candida Cristina Quarta; Carol Whelan; Aviva Petrie; Dorota Rowczenio; Janet A. Gilbertson; David F. Hutt; Tamer Rezk; Svetla Strehina; Joan Caringal-Galima; Richa Manwani; Faye Sharpley; Ashutosh Wechalekar; Helen J. Lachmann; Shameem Mahmood; Sajitha Sachchithanantham; Edmund Drage; Harvey Jenner; Rosie McDonald; Ottavia Bertolli; Alan Calleja; Philip N. Hawkins; Julian D. Gillmore

doi:10.1161/circulationaha.118.038169

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

ATTR-CM is an inexorably progressive and eventually fatal cardiomyopathy associated with poor quality of life. Diagnosis is often delayed for many years after symptoms develop. Improved awareness and wider use of recently validated diagnostic imaging methods are urgently required for patients to benefit from recent therapeutic developments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lane et al. (2019) studied this question.

synapsesocial.com/papers/69dbe013498b35d3e6a3d6c4 https://doi.org/10.1161/circulationaha.118.038169

View Full Paper

Ask AI

Bookmark

Share

Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis

Ask about this paper

Abstract

Discussion

Cite This Study

Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading